Posted inCardiology Internal Medicine news
PCSK9 Inhibition Lowers LDL Cholesterol in Heterozygous Familial Hypercholesterolemia Regardless of LDL Receptor Variant Function
In a pooled nonrandomized phase 3 analysis, monthly lerodalcibep reduced LDL-C by about 50% in heterozygous familial hypercholesterolemia, with similar efficacy across LDLR functional variant categories and broad attainment of guideline-based LDL-C goals.